Ogan Gurel, MD MPhil, CEO of Duravest, Inc., (OTC
BB:DUVT, XETRA:DUV) capped breakfast and luncheon meetings yesterday
with members of the Wall Street financial community with a dinner
meeting with the Financial Investment Analysts (FIA) at which he gave
a presentation of the company's history and present and future
prospects and answered questions from the assembled groups. The
meetings were prompted by the intense interest in Duravest since it
announced (October 28, 2005) the successful preliminary results of its
subsidiary Estracure's Phase II "proof-of-concept" clinical trial with
17-beta-estradiol. The results were first revealed at the recent
Canadian Cardiovascular Congress by Dr Jean-Francois Tanguay, MD,
CPSQ, FRCP of the Montreal Heart Institute and Chief Scientific
Officer of Estracure.
"I was very pleased," Dr. Gurel commented, "by the strong level of engagement and the deep knowledge displayed by the people we met regarding the restenosis problem as well as the critical importance of safety for medical devices in general and with drug-eluting stents in particular. We were very encouraged by the interest expressed in our estrogen-eluting stent as a as a potential replacement technology in the multi-billion dollar coronary stent market. I look forward to meeting again with them and with other members of the financial community in the coming months."
As part of this first-ever Duravest road-show, Dr. Gurel will also be in Frankfurt next week for additional investor meetings as part of the Deutsches Eigenkapitalforum investor conference. These meetings - as well as the company's European based investor relations work - have been organized by Close Brothers Seydler AG which is one of Germany's leadings securities houses. Rene Parmantier, Executive Director at Close Brothers Seydler AG remarked, "We are looking forward to presenting the Duravest story in the German capital markets. The Deutsche Eigenkapitalforum is the ideal platform to meet investors, press and analysts in Germany."
The Estracure Phase II trial compared the safety and efficacy of 17-beta-estradiol at the site of conventional angioplasty/stenting and displayed a strong trend towards reductions in clinical restenosis. The patients receiving locally administered 17-beta-estradiol experienced one-third less major adverse cardiac events (MACE) and over two-thirds reduction in urgent percutaneous coronary intervention (PCI). Animal (pig) trials with the proprietary 17-beta-estradiol drug eluting stents are already in progress and Phase III trials using these stents in human patients are planned in Europe in the first half of 2006. The worldwide coronary stent market was $5.1 billion in 2004 and is estimated to grow to $ 5.8 billion in 2008.
Safe Harbor Forward Looking Statements
This release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals or assumptions of future events are not statements of historical fact and may be considered forward looking statements. They involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated.
"I was very pleased," Dr. Gurel commented, "by the strong level of engagement and the deep knowledge displayed by the people we met regarding the restenosis problem as well as the critical importance of safety for medical devices in general and with drug-eluting stents in particular. We were very encouraged by the interest expressed in our estrogen-eluting stent as a as a potential replacement technology in the multi-billion dollar coronary stent market. I look forward to meeting again with them and with other members of the financial community in the coming months."
As part of this first-ever Duravest road-show, Dr. Gurel will also be in Frankfurt next week for additional investor meetings as part of the Deutsches Eigenkapitalforum investor conference. These meetings - as well as the company's European based investor relations work - have been organized by Close Brothers Seydler AG which is one of Germany's leadings securities houses. Rene Parmantier, Executive Director at Close Brothers Seydler AG remarked, "We are looking forward to presenting the Duravest story in the German capital markets. The Deutsche Eigenkapitalforum is the ideal platform to meet investors, press and analysts in Germany."
The Estracure Phase II trial compared the safety and efficacy of 17-beta-estradiol at the site of conventional angioplasty/stenting and displayed a strong trend towards reductions in clinical restenosis. The patients receiving locally administered 17-beta-estradiol experienced one-third less major adverse cardiac events (MACE) and over two-thirds reduction in urgent percutaneous coronary intervention (PCI). Animal (pig) trials with the proprietary 17-beta-estradiol drug eluting stents are already in progress and Phase III trials using these stents in human patients are planned in Europe in the first half of 2006. The worldwide coronary stent market was $5.1 billion in 2004 and is estimated to grow to $ 5.8 billion in 2008.
Safe Harbor Forward Looking Statements
This release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals or assumptions of future events are not statements of historical fact and may be considered forward looking statements. They involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated.